Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage

Southern Medical Journal

Volumn 103, Issue 5, 2010, Pages 398-402

  Hassan, Ameer E ^a   Hassanzadeh, Bahareh ^a   Tohidi, Vahid ^a   Kirmani, Jawad F ^a  

^a NONE

Author keywords

Acute ischemic stroke; Intracranial hemorrhage; IV rt PA; Mild stroke; MRS

Indexed keywords

ALTEPLASE;

ACUTE DISEASE; ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; RANKIN SCALE; STROKE PATIENT; TREATMENT OUTCOME;

BRAIN ISCHEMIA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77951799619     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e3181d7814a     Document Type: Article

References (25)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. American Heart Association, Dallas, TX.
2. Hacke W, Donnan G, Fieschi C, et al; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363: 768-774.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
4. Kimura K, Iguchi Y, Yamashita S, et al. Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci 2008;267:57-61. (Pubitemid 351248907)
5. Hacke W, Kaste M, Bluhmki E, et al; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
6. Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-1020. (Pubitemid 32336306)
7. Katzan IL, Hammer MD, Hixson ED, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346-350. (Pubitemid 38327350)
8. Kleindorfer D, Kissela B, Schneider A, et al; Neuroscience Institute. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004;35:e27-e29.
9. Cocho D, Belvís R, Martí-Fàbregas J, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005; 64:719-720. (Pubitemid 40261906)
10. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340: 1781-1787. (Pubitemid 29266401)
11. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005;46:243-252. (Pubitemid 41218712)
12. Broderick JP, Lu M, Kothari R, et al. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 2000;10:2335-2341.
13. Adams HP Jr, del Zoppo G, Alberts MJ, et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-1711.
14. Smith EE, Abdullah AR, Petkovska I, et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005;36:2497-2499. (Pubitemid 41566987)
15. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-870. (Pubitemid 19188240)
16. Van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19: 604-607.
17. Hommel M, Boissel JP, Cornu C, et al. Termination of trial of streptokinase in severe acute ischemic stroke. MAST Study Group. Lancet 1995;345:57.
18. Donnan GA, Hommel M, Davis SM, et al. Streptokinase in acute isch-aemic stroke. Steering Committees of the ASK and MAST-E trials. Australian Streptokinase Trial. Lancet 1995;346:56.
19. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-1025.
20. Vaishnav AG, Pettigrew LC, Ryan S. Telephonic guidance of systemic thrombolysis in acute ischemic stroke: safety outcome in rural hospitals. Clin Neurol Neurosurg 2008;110:451-454.
21. Baumann CR, Baumgartner RW, Gandjour J, et al. Good outcomes in ischemic stroke patients treated with intravenous thrombolysis despite regressing neurological symptoms. Stroke 2006;37:1332-1333. (Pubitemid 43731885)
22. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al; German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831-1838. (Pubitemid 40169293)
23. Sylaja PN, Cote R, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006;77:826-829. (Pubitemid 44023176)
24. Simon JE, Sandler DL, Pexman JH, et al; Calgary Stroke Programme. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? Age Ageing 2004;33:143-149.
25. Engelter ST, Reichhart M, Sekoranja L, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795-1798. (Pubitemid 43754415)